News
Another cell therapy biotech has run out of steam, this time before ever reaching the clinic. | Another cell therapy biotech ...
While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...
Dealbreaker on MSN8h
Gilead Sciences Gains In Vivo Cell Therapy Capability With $350M Interius Bio Acquisition
Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...
MyChesCo on MSN15h
Kite to Buy Interius BioTherapeutics for $350 Million, Advancing In Vivo CAR T Strategy
Kite, a Gilead company (Nasdaq: GILD), has agreed to acquire Interius BioTherapeutics for $350 million in cash, a move aimed at bringing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback